Buy Dr Lal Pathlabs; target of Rs 2100: Emkay Global Financial

Emkay Global Financial' research report on Dr Lal PathlabsDLPL has announced the acquisition of SN Genelab—a B2B diagnostics operator focused on advanced genomics and molecular pathology testing—for Rs1.68bn (70% stake), thus valuing the company at ~16x FY26 EV/EBITDA. We expect the company to cros…